More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$49.67B
EPS
0.44
P/E ratio
67.3
Price to sales
2.77
Dividend yield
--
Beta
0.852297
Previous close
$44.50
Today's open
$44.30
Day's range
$42.52 - $44.57
52 week range
$26 - $44.57
show more
CEO
Richard D. Francis
Employees
33950
Headquarters
Parsippany, NJ
Exchange
New York Stock Exchange
Shares outstanding
1.17B
Issue type
Common Stock
Healthcare
Pharmaceuticals
David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes
DME Capital Management LP, founded and led by well-known investor David Einhorn , unveiled its newest third-quarter stock positions and fund changes on Monday. Here are the latest moves.
Benzinga • 12 hours ago

FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use.
Benzinga • Nov 16, 2026

Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
Teva Pharmaceutical Industries NYSE: TEVA outlined plans to grow its innovative medicines business and advance a pipeline spanning neuroscience, immunology and cancer treatments at its first R&D Day.
MarketBeat • Nov 11, 2026

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma.
GlobeNewsWire • Nov 11, 2026

Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
Teva improved margins significantly. The pharmaceutical company has paid down net debt.
The Motley Fool • Nov 6, 2026

What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call
Teva Pharmaceutical Industries NYSE: TEVA reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by lower generic-drug sales, particularly generic REVLIMID.
MarketBeat • Nov 4, 2026

Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.
Zacks Investment Research • Nov 4, 2026

Teva Pharmaceutical Q3 profit gain beats estimates
Israeli drugmaker Teva Pharmaceutical Industries, reported on Tuesday a higher-than-expected rise in third-quarter profit, helped by strong sales of a trio of its own drugs to offset declines in copycat medicines.
Reuters • Nov 3, 2026

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo
Teva Pharmaceutical Industries expects to grow in 2027 despite the US inflation reduction act that will cap prices for its top branded drug Austedo to treat Huntington's Disease and Tardive Dyskinesia, CEO Richard Francis said on Tuesday.
Reuters • Nov 3, 2026

Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat
Teva stock advanced early Tuesday on better-than-expected third-quarter metrics and a raised outlook for 2026.
Investors Business Daily • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Teva Pharmaceutical Industries Limited commission-free¹. Build wealth for the long term using automated trading and transfers.